glp-1 agonists oral glp-1_analogs [TUSOM FDA just approved orforglipron (Foundayo),
Description
The key difference was that exendin-4 remained active in the body far longer than its human counterpart
Rapid dose escalation
GLP-3 is a synthetic multi-receptor peptide analog currently being investigated in laboratory research settings for its interaction with multiple metabolic signaling pathways
Klein S, Nestor JJ, Harris MS, Suyundikov A, Casper R, Steele SM, et al
Furthermore, even after the initiation of insulin therapy, uncertainty remains regarding which additional antihyperglycaemic agents should be introduced and at what stage, especially in the context of long-term GCs treatment
